- authorisedTherapeutic exploratory (Phase II)
Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.
This study is looking at a new, stronger chemotherapy treatment for people with high-risk Ewing Sarcoma. It combines medicines like Treosulfan and Melphalan to see how safe and effective they are. The aim is to find better ways to stop this cancer from coming back.
Italy - recruitingPHASE1, PHASE2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
This study is testing a new drug, Zilovertamab Vedotin, for children and young adults aged 6 months to 25 years with certain blood cancers (like some types of leukaemia and lymphoma) and solid tumours (like neuroblastoma and Ewing sarcoma) that have come back or not responded to previous treatments.
United States · Australia · Belgium - recruitingPHASE2
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
This study is looking at a new combination of two drugs, pembrolizumab and cabozantinib, for people with advanced sarcomas. The aim is to see if this combination can help shrink tumours or slow their growth in three types of sarcoma.
France - active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
United States · Brazil · Canada - recruitingPHASE1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This early-stage study is testing a new drug, INBRX-109, for people with advanced solid tumours, including certain types of Ewing sarcoma and bowel cancer. Researchers want to see if it's safe and how well it works, both alone and with standard treatments. This is for patients who haven't responded to previous therapies.
United States · France · Italy